Skip to content
Clinical Trials – home
FranceBack to France

Clinical trials in Neuilly-Sur-Seine – page 21

3 430 clinical trials in Neuilly-Sur-Seine, France across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Neuilly-Sur-Seine at a glance
3 430
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

3 430 trials in Neuilly-Sur-Seine

Open in trial search

Bladder cancer

Recruiting

Study of Enfortumab Vedotin and Pembrolizumab for Bladder Preservation in Patients with Muscle‑Invasive Bladder Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Enfortumab Vedotin
  • Sponsor:Astellas Pharma Global Development Inc.

Long‑Term Monitoring of Malignancy Risk in Early‑Onset Metachromatic Leukodystrophy Patients Treated with atidarsagene autotemcel

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:Atidarsagene Autotemcel
  • Sponsor:Orchard Therapeutics (Europe) Limited

Long‑Term Safety Study of ADX‑324 in Participants with Hereditary Angioedema (Phase 3 Extension)

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:ADX-324
  • Sponsor:Adarx Pharmaceuticals Inc.

Gastric cancer+1

Recruiting

Study of AZD0901 (sonesitatug vedotin) with capecitabine ± rilvegostomig in adults with advanced stomach or esophageal cancer (Claudin‑18.2‑positive, HER2‑negative)

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:AZD0901
  • Sponsor:AstraZeneca AB

Effectiveness and Safety of Pegcetacoplan in Patients with C3 Glomerulopathy or Primary Immune Complex Membranoproliferative Glomerulonephritis

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Pegcetacoplan
  • Sponsor:Swedish Orphan Biovitrum AB (publ)

Efficacy and safety of sarilumab plus prednisone versus prednisone alone in adults with early polymyalgia rheumatica

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Prednisone
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Study of MK-1045 versus blinatumomab with tocilizumab in patients with relapsed or refractory B-cell acute lymphoblastic leukemia

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Blinatumomab
  • Sponsor:Merck Sharp & Dohme LLC

Study of MK-1084 plus durvalumab versus placebo plus durvalumab in patients with locally advanced KRAS G12C‑mutant non‑small cell lung cancer after chemoradiotherapy

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Merck Sharp & Dohme LLC

Study of denikitug alone or with drug combination in adults with HER2‑negative metastatic gastric, gastroesophageal junction and esophageal adenocarcinoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Denikitug
  • Sponsor:Gilead Sciences Inc.

Venetoclax added to fludarabine, cytarabine and gemtuzumab ozogamicin (drug combination) in children with relapsed acute myeloid leukemia

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:Azacitidine
  • Sponsor:Prinses Maxima Centrum voor Kinderoncologie B.V.

Phase 1/2 Study of VS-7375 with Drug Combination in Patients with Advanced KRAS G12D‑Mutated Solid Tumors

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Verastem Inc.

Vitiligo

Recruiting

Phase IIb Randomized, Double‑Blind Study of GIA632 in Adults with Nonsegmental Vitiligo

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:GIA632
  • Sponsor:Novartis Pharma AG

Other cities in France

The busiest research cities in the country

All 376 cities in France

Clinical research in Neuilly-Sur-Seine

What the registry says about research in the country

01 Gastrointestinal Research

Extensive clinical trials focusing on inflammatory bowel diseases, particularly investigating innovative treatments for Crohn's Disease and Ulcerative Colitis. Multiple studies are evaluating novel therapeutic approaches for patients with moderate to severe conditions.

  • Crohn's Disease Management
  • Ulcerative Colitis Treatments
  • Post-operative Care Studies

Research includes both induction and maintenance therapies, with emphasis on long-term patient outcomes.

02 Cardiovascular Studies

Innovative research in cardiac conditions, including studies on acute myocarditis treatment and prevention of post-operative complications. Trials are examining both therapeutic and preventive approaches.

  • Myocarditis Treatment
  • Post-operative Care
  • Cardiac Surgery Outcomes

Focus on improving patient outcomes through targeted interventions and innovative surgical techniques.

03 Oncology Research

Advanced studies in cancer treatment, including trials for head and neck squamous cell carcinoma and colorectal cancer. Research focuses on both targeted therapies and combination treatments.

  • Metastatic Cancer Treatment
  • Colorectal Cancer Management
  • Prostate Cancer Therapy

Emphasis on developing personalized treatment approaches and improving survival rates.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.